Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Yousif Capital Management LLC

Yousif Capital Management LLC boosted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,775 shares of the medical research company’s stock after buying an additional 51 shares during the quarter. Yousif Capital Management LLC’s holdings in Bio-Rad Laboratories were worth $896,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA purchased a new position in Bio-Rad Laboratories in the 3rd quarter valued at approximately $116,036,000. Parnassus Investments LLC purchased a new position in shares of Bio-Rad Laboratories in the third quarter valued at $79,143,000. Deerfield Management Company L.P. Series C acquired a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth $62,351,000. Earnest Partners LLC boosted its position in shares of Bio-Rad Laboratories by 25.6% in the 3rd quarter. Earnest Partners LLC now owns 351,510 shares of the medical research company’s stock worth $125,999,000 after buying an additional 71,570 shares in the last quarter. Finally, QVIDTVM Management LLC acquired a new stake in Bio-Rad Laboratories in the 3rd quarter valued at about $24,794,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Michael Crowley sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the transaction, the executive vice president now owns 6,942 shares of the company’s stock, valued at $2,332,512. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 17.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on BIO shares. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their target price for the stock from $400.00 to $365.00 in a research report on Wednesday, April 3rd. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Royal Bank of Canada dropped their price target on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. Finally, UBS Group upped their price objective on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a research report on Friday, February 16th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $468.00.

Bio-Rad Laboratories Trading Up 0.2 %

Shares of BIO opened at $279.83 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $468.45. The stock has a fifty day moving average of $318.52 and a two-hundred day moving average of $314.90. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83. The company has a market capitalization of $7.98 billion, a PE ratio of -13.02 and a beta of 0.94.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The firm had revenue of $681.18 million for the quarter, compared to the consensus estimate of $685.00 million. During the same period in the prior year, the business posted $3.31 earnings per share. The firm’s revenue for the quarter was down 6.7% compared to the same quarter last year. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.